CAS: 147438-30-0; (S)-1-(2-((2R,3R,6S)-6-((2S,3E,5E,7E,9S,11R)-2,13-Dimethoxy-3,9,11-Trimethyl-12-Oxotrideca-3,5,7-Trien-1-yl)-2-Hydroxy-3-Methyltetrahydro-2H-Pyran-2-yl)-2-Oxoacetyl)Piperidine-2-Carboxylic Acid
- 英文名称(S)-1-(2-((2R,3R,6S)-6-((2S,3E,5E,7E,9S,11R)-2,13-Dimethoxy-3,9,11-Trimethyl-12-Oxotrideca-3,5,7-Trien-1-yl)-2-Hydroxy-3-Methyltetrahydro-2H-Pyran-2-yl)-2-Oxoacetyl)Piperidine-2-Carboxylic Acid
- 中文名称依维莫司杂质 05
- IUPAC名称(S)-1-(2-((2R,3R,6S)-6-((2S,3E,5E,7E,9S,11R)-2,13-dimethoxy-3,9,11-trimethyl-12-oxotrideca-3,5,7-trien-1-yl)-2-hydroxy-3-methyltetrahydro-2H-pyran-2-yl)-2-oxoacetyl)piperidine-2-carboxylic acid
- 其它别名(2S)-1-[2-[(2R,3R,6S)-6-[(2S,3E,5E,7E,9S,11R)-2,13-Dimethoxy-3,9,11-Trimethyl-12-Oxo-3,5,7-Tridecatrien-1-Yl]Tetrahydro-2-Hydroxy-3-Methyl-2H-Pyran-2-Yl]-2-Oxoacetyl]-2-Piperidinecarboxylic Acid; Everolimus Impurity 3; Everolimus Related Compound; (S)-1-(2-((2R,3R,6S)-6-((2S,3E,5E,7E,9S,11R); 2-Piperidinecarboxylic Acid, 1-[2-[(2R,3R,6S)-6-[(2S,3E,5E,7E,9S,11R)-2,13-Dimethoxy-3,9,11-Trimethyl-12-Oxo-3,5,7-Tridecatrien-1-Yl]Tetrahydro-2-Hydroxy-3-Methyl-2H-Pyran-2-Yl]-2-Oxoacetyl]-, (2S)-; (2S) -1- [2- [(2R, 3R, 6S) - 6- [(2S, 3E, 5E, 7E, 9S, 11R) - 2, 13- Dimethoxy- 3, 9, 11- Trimethyl- 12- Oxo- 3, 5, 7- Tridecatrien- 1- Yl] Tetrahydro- 2- Hydroxy- 3- Methyl- 2H- Pyran- 2- Yl] - 2- Oxo; (2S)-1-[[(2R,3R,6S)-6-[(2S,3E,5E,7E,9S,11R)-2,13-Dimethoxy-3,9,11-Trimethyl-12-Oxo-3,5,7-Tridecatrienyl]Tetrahydro-2-Hydroxy-3-Methyl-2H-Pyran-2-Yl]Oxoacetyl]-2-Piperidinecarboxylic Acid
- CAS编号147438-30-0
- FDA UNII编号:XH5W3BP9LC
- 分子式:C32H49NO9分子量:591.74
- 产品CID: 704942
- 产品分类分析化学 → 标准品 → 药典标准品和杂质标准品
物理性质
MSDS等安全信息
上下游产品
28-secorapamycin sirolimus (S)-1-{2-[(2R,3R,6S)-6-((3E,5E,7E)-(2S,9S,11R)-2,13-Dimethoxy-3,9,11-trimethyl-12-oxo-trideca-3,5,7-trienyl)-2-hydroxy-3-methyl-tetrahydro-pyran-2-yl]-2-oxo-acetyl}-piperidine-2-carboxylic acid tert-butyl ester (8E,10E,12E)-(2R,5S,7S,14S,16R)-5-(tert-Butyl-dimethyl-silanyloxy)-7,18-dimethoxy-2,8,14,16-tetramethyl-17-oxo-°Ctadeca-8,10,12-trienal合成工艺路线路线简述
📜雷帕霉素置于1,8-二氮杂双环[5.4.0]十一碳-7-烯,Zinc(II) Chloride体系中,用 四氢呋喃 用作溶剂,化学反应 50.0H,反应生成依维莫司杂质3
参考文献:Studies On The Chemistry Of Rapamycin: Novel Transformations Under Lewis-Acid Catalysis
标题:Studies On The Chemistry Of Rapamycin: Novel Transformations Under Lewis-Acid Catalysis
摘要:The Reactivity Of Rapamycin Under Mild Lewis-Acid Catalysis Has Been Investigated. The Molecule Has Been Found To Be Extremely Sensitive To Basic Reagents Due To Carboxylate Elimination Beta To The C24 Ketone. However,Transformations Normally Effected Under Basic Conditions,Such As C-13-C-14 Benzilic Acid Rearrangement Of C28-C30 Retroaldol,Can Be Achieved On Rapamycin Itself By Catalysis With Zncl2 In The Appropriate Solvent. These Are Novel Transformations That Circumvent The Protection Or Masking Of Reactive Functional Groups And Allow Efficient Degradation Of The Molecule For Synthetic And Biological Studies.
Doi:10.1016/s0040-4039(00)77473-9
海关参考信息
- 2901210000-乙烯
2901220000-丙烯
2901241000-1,3-丁二烯
2905122000-异丙醇 - 💡 提示：海关信息按照顺序优先匹配，如需确认的海关信息，请参考相关资料。
- 详情请参考：📖 海关编码查询和海关进出口税则
供应商参考报价(招募中)
品牌试剂参考报价(招募中)
📌 第三方产品分析报告
主要参考文献
参考标题:Total Synthesis Of Rapamycin Via A Novel Titanium-Mediated Aldol Macrocyclization Reaction作者:Cheryl M. Hayward,Daniel Yohannes,Samuel J. Danishefsky |发布日期:1993.10
合成参考文献
合成方法参考DOI号:10.1016/S0040-4039(00)77473-9
📝 需求与反馈
尽可能描述清楚需求与问题信息
